Cytokines and Inflammatory Response in the Fetus and Neonate

Fetal and Neonatal Physiology, 2-Volume Set

Volumn , Issue , 2017, Pages 1241-1254.e4

  Srinivasan, Lakshmi ^a   Harris, Mary Catherine ^a   Kilpatrick, Laurie E ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85136010931     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-35214-7.00128-1     Document Type: Chapter

References (311)

1. R Medzhitov (2008) Origin and physiological roles of inflammation. Nature 454 428-435.
2. R Medzhitov (2010) Inflammation 2010: new adventures of an old flame. Cell 140 771-776.
3. R Medzhitov (2007) Recognition of microorganisms and activation of the immune response. Nature 449 819-826.
4. WG Land (2011) Oxidative injury-induced, damage associated molecular pattern molecules and their pattern recognition receptors. WG Land (Ed.) Innate alloimmunity: part II—innate immunity and rejection Lengerich, Germany: Baskent University-Pabst Science Publishers 229-337.
5. MJ Mondrinos, PA Kennedy, M Lyons, et al. (2013) Protein kinase C and acute respiratory distress syndrome. Shock 39 467-479.
6. LB Tolle and TJ Standiford (2013) Danger-associated molecular patterns (DAMPs) in acute lung injury. J Pathol 229 145-156.
7. AM Piccinini and KS Midwood (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm Epub Jul 13
8. TH Mogensen (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22 240-273.
9. CA Dinarello (2007) Historical insights into cytokines. Eur J Immunol 37(Suppl 1), S34-S45.
10. CA Dinarello (2000) Proinflammatory cytokines. Chest 118 503-508.
11. M Kopf, MF Bachmann and BJ Marsland (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9 703-718.
12. JR Tisoncik, MJ Korth, CP Simmons, et al. (2012) Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76 16-32.
13. P Boontham, P Chandran, B Rowlands, et al. (2003) Surgical sepsis: dysregulation of immune function and therapeutic implications. Surgeon 1 187-206.
14. SM Opal and VA DePalo (2000) Anti-inflammatory cytokines. Chest 117 1162-1172.
15. T van der Poll and SJ van Deventer (1999) Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 13 413-426.
16. D Pennica, GE Nedwin, JS Hayflick, et al. (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312 724-729.
17. RA Black, CT Rauch, CJ Kozlosky, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 729-733.
18. BB Aggarwal (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3 745-756.
19. DJ MacEwan (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14 477-492.
20. H Loetscher, YC Pan, HW Lahm, et al. (1990) Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61 351-359.
21. TJ Schall, M Lewis, KJ Koller, et al. (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61 361-370.
22. Z Dembic, H Loetscher, U Gubler, et al. (1990) Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 2 231-237.
23. G Chen and DV Goeddel (2002) TNF-R1 signaling: a beautiful pathway. Science 296 1634-1635.
24. SI Grivennikov, DV Kuprash, ZG Liu, et al. (2006) Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms. Int Rev Cytol 252 129-161.
25. T Hehlgans and K Pfeffer (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 1-20.
26. O Micheau and J Tschopp (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 181-190.
27. TL Haas, CH Emmerich, B Gerlach, et al. (2009) Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 36 831-844.
28. AT Ting, FX Pimentel-Muinos and B Seed (1996) RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J 15 6189-6196.
29. MA Kelliher, S Grimm, Y Ishida, et al. (1998) The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8 297-303.
30. A Devin, A Cook, Y Lin, et al. (2000) The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 12 419-429.
31. WH Kutteh, WE Rainey, B Beutler, et al. (1991) Tumor necrosis factor-alpha and interleukin-1 beta production by human fetal Kupffer cells. Am J Obstet Gynecol 165 112-120.
32. WH Kutteh, WE Rainey and BR Carr (1991) Regulation of interleukin-6 production in human fetal Kupffer cells. Scand J Immunol 33 607-613.
33. R Romero, M Mazor, W Sepulveda, et al. (1992) Tumor necrosis factor in preterm and term labor. Am J Obstet Gynecol 166 1576-1587.
34. JR Challis, CJ Lockwood, L Myatt, et al. (2009) Inflammation and pregnancy. Reprod Sci 16 206-215.
35. R Arsenescu, V Arsenescu and WJ de Villiers (2011) TNF-alpha and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 106 559-562.
36. M Pasparakis, L Alexopoulou, V Episkopou, et al. (1996) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184 1397-1411.
37. B Feldhaus, ID Dietzel, R Heumann, et al. (2004) Effects of interferon-gamma and tumor necrosis factor-alpha on survival and differentiation of oligodendrocyte progenitors. J Soc Gynecol Investig 11 89-96.
38. MC Seghaye, W Heyl, RG Grabitz, et al. (1998) The production of pro- and anti-inflammatory cytokines in neonates assessed by stimulated whole cord blood culture and by plasma levels at birth. Biol Neonate 73 220-227.
39. AM Peters, P Bertram, M Gahr, et al. (1993) Reduced secretion of interleukin-1 and tumor necrosis factor-alpha by neonatal monocytes. Biol Neonate 63 157-162.
40. E Förster-Waldl, K Sadeghi, D Tamandl, et al. (2005) Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res 58 121-124.
41. DF Angelone, MR Wessels, M Coughlin, et al. (2006) Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-α production in vitro and in vivo. Pediatr Res 60 205-209.
42. SK Burchett, WM Weaver, JA Westall, et al. (1988) Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol 140 3473-3481.
43. S Chheda, KH Palkowetz, R Garofalo, et al. (1996) Decreased interleukin-10 production by neonatal monocytes and T cells: relationship to decreased production and expression of tumor necrosis factor-alpha and its receptors. Pediatr Res 40 475-483.
44. DJ Kwak, NH Augustine, WG Borges, et al. (2000) Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci. Infect Immun 68 320-327.
45. CA Dinarello (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20 S1-S13.
46. C Dinarello, W Arend, J Sims, et al. (2010) IL-1 family nomenclature. Nat Immunol 11 973.
47. JE Sims and DE Smith (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10 89-102.
48. C Garlanda, CA Dinarello and A Mantovani (2013) The interleukin-1 family: back to the future. Immunity 39 1003-1018.
49. AC Webb, KL Collins, PE Auron, et al. (1986) Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res 5 77-85.
50. D Ferrari, C Pizzirani, E Adinolfi, et al. (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176 3877-3883.
51. R Medzhitov (2008) Origin and physiological roles of inflammation. Nature 454 428-435.
52. R Medzhitov (2010) Inflammation 2010: new adventures of an old flame. Cell 140 771-776.
53. R Medzhitov (2007) Recognition of microorganisms and activation of the immune response. Nature 449 819-826.
54. WG Land (2011) Oxidative injury-induced, damage associated molecular pattern molecules and their pattern recognition receptors. WG Land (Eds) Innate alloimmunity: part II—innate immunity and rejection Lengerich, Germany: Baskent University-Pabst Science Publishers 229-337.
55. MJ Mondrinos, PA Kennedy, M Lyons, et al. (2013) Protein kinase C and acute respiratory distress syndrome. Shock 39 467-479.
56. LB Tolle and TJ Standiford (2013) Danger-associated molecular patterns (DAMPs) in acute lung injury. J Pathol 229 145-156.
57. AM Piccinini and KS Midwood (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm Epub Jul 13
58. TH Mogensen (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22 240-273.
59. CA Dinarello (2007) Historical insights into cytokines. Eur J Immunol 37(Suppl 1), S34-S45.
60. CA Dinarello (2000) Proinflammatory cytokines. Chest 118 503-508.
61. M Kopf, MF Bachmann and BJ Marsland (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9 703-718.
62. JR Tisoncik, MJ Korth, CP Simmons, et al. (2012) Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76 16-32.
63. P Boontham, P Chandran, B Rowlands, et al. (2003) Surgical sepsis: dysregulation of immune function and therapeutic implications. Surgeon 1 187-206.
64. SM Opal and VA DePalo (2000) Anti-inflammatory cytokines. Chest 117 1162-1172.
65. T van der Poll and SJ van Deventer (1999) Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 13 413-426.
66. D Pennica, GE Nedwin, JS Hayflick, et al. (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312 724-729.
67. RA Black, CT Rauch, CJ Kozlosky, et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 729-733.
68. BB Aggarwal (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3 745-756.
69. DJ MacEwan (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14 477-492.
70. H Loetscher, YC Pan, HW Lahm, et al. (1990) Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61 351-359.
71. TJ Schall, M Lewis, KJ Koller, et al. (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61 361-370.
72. Z Dembic, H Loetscher, U Gubler, et al. (1990) Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 2 231-237.
73. G Chen and DV Goeddel (2002) TNF-R1 signaling: a beautiful pathway. Science 296 1634-1635.
74. SI Grivennikov, DV Kuprash, ZG Liu, et al. (2006) Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms. Int Rev Cytol 252 129-161.
75. T Hehlgans and K Pfeffer (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 1-20.
76. O Micheau and J Tschopp (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 181-190.
77. TL Haas, CH Emmerich, B Gerlach, et al. (2009) Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 36 831-844.
78. AT Ting, FX Pimentel-Muinos and B Seed (1996) RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J 15 6189-6196.
79. MA Kelliher, S Grimm, Y Ishida, et al. (1998) The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8 297-303.
80. A Devin, A Cook, Y Lin, et al. (2000) The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 12 419-429.
81. WH Kutteh, WE Rainey, B Beutler, et al. (1991) Tumor necrosis factor-alpha and interleukin-1 beta production by human fetal Kupffer cells. Am J Obstet Gynecol 165 112-120.
82. WH Kutteh, WE Rainey and BR Carr (1991) Regulation of interleukin-6 production in human fetal Kupffer cells. Scand J Immunol 33 607-613.
83. R Romero, M Mazor, W Sepulveda, et al. (1992) Tumor necrosis factor in preterm and term labor. Am J Obstet Gynecol 166 1576-1587.
84. JR Challis, CJ Lockwood, L Myatt, et al. (2009) Inflammation and pregnancy. Reprod Sci 16 206-215.
85. R Arsenescu, V Arsenescu and WJ de Villiers (2011) TNF-alpha and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 106 559-562.
86. M Pasparakis, L Alexopoulou, V Episkopou, et al. (1996) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184 1397-1411.
87. B Feldhaus, ID Dietzel, R Heumann, et al. (2004) Effects of interferon-gamma and tumor necrosis factor-alpha on survival and differentiation of oligodendrocyte progenitors. J Soc Gynecol Investig 11 89-96.
88. MC Seghaye, W Heyl, RG Grabitz, et al. (1998) The production of pro- and anti-inflammatory cytokines in neonates assessed by stimulated whole cord blood culture and by plasma levels at birth. Biol Neonate 73 220-227.
89. AM Peters, P Bertram, M Gahr, et al. (1993) Reduced secretion of interleukin-1 and tumor necrosis factor-alpha by neonatal monocytes. Biol Neonate 63 157-162.
90. E Förster-Waldl, K Sadeghi, D Tamandl, et al. (2005) Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res 58 121-124.
91. DF Angelone, MR Wessels, M Coughlin, et al. (2006) Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-α production in vitro and in vivo. Pediatr Res 60 205-209.
92. SK Burchett, WM Weaver, JA Westall, et al. (1988) Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol 140 3473-3481.
93. S Chheda, KH Palkowetz, R Garofalo, et al. (1996) Decreased interleukin-10 production by neonatal monocytes and T cells: relationship to decreased production and expression of tumor necrosis factor-alpha and its receptors. Pediatr Res 40 475-483.
94. DJ Kwak, NH Augustine, WG Borges, et al. (2000) Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci. Infect Immun 68 320-327.
95. CA Dinarello (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20 S1-S13.
96. C Dinarello, W Arend, J Sims, et al. (2010) IL-1 family nomenclature. Nat Immunol 11 973.
97. JE Sims and DE Smith (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10 89-102.
98. C Garlanda, CA Dinarello and A Mantovani (2013) The interleukin-1 family: back to the future. Immunity 39 1003-1018.
99. AC Webb, KL Collins, PE Auron, et al. (1986) Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res 5 77-85.
100. D Ferrari, C Pizzirani, E Adinolfi, et al. (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176 3877-3883.
101. NA Thornberry, HG Bull, JR Calaycay, et al. (1992) A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356 768-774.
102. F Martinon and J Tschopp (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14 10-22.
103. MG Netea, A Simon, F van de Veerdonk, et al. (2010) IL-1β processing in host defense: beyond the inflammasomes. PLoS Pathog 6 e1000661.
104. LA O'Neill (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226 10-18.
105. A Dunne and LA O'Neill (2003) The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003(171), re3.
106. LA O'Neill and AG Bowie (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7 353-364.
107. LA O'Neill (2006) How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 18 3-9.
108. M Muzio, J Ni, P Feng, et al. (1997) IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278 1612-1615.
109. Z Cao, WJ Henzel and X Gao (1996) IRAK: a kinase associated with the interleukin-1 receptor. Science 271 1128-1131.
110. N Suzuki, S Suzuki, GS Duncan, et al. (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416 750-756.
111. J Ninomiya-Tsuji, K Kishimoto, A Hiyama, et al. (1999) The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398 252-256.
112. A Hebra, P Strange, JM Egbert, et al. (2001) Intracellular cytokine production by fetal and adult monocytes. J Pediatr Surg 36 1321-1326.
113. H Bessler, L Sirota, I Notti, et al. (1993) IL-1β and IL-3-like activity in preterm infants. Clin Exp Immunol 91 320-324.
114. CA Dinarello, M Shparber, EF Kent Jr, et al. (1981) Production of leukocytic pyrogen from phagocytes of neonates. J Infect Dis 144 337-343.
115. RW Wilmott, MC Harris, KM Haines, et al. (1987) Interleukin-1 activity from human cord blood monocytes. Diagn Clin Immunol 5 201-204.
116. I Srugo, A Berger, Z Lapidot, et al. (1991) Interleukin-1 secretion by blood monocytes of septic premature infants. Infection 19 150-154.
117. K Bry, U Lappalainen, F Waffarn, et al. (1994) Influence of fetal gender on the concentration of interleukin-1 receptor antagonist in amniotic fluid and in newborn urine. Pediatr Res 35 130-134.
118. E Elsmen, D Ley, CM Cilio, et al. (2006) Umbilical cord levels of interleukin-1 receptor antagonist and neonatal outcome. Biol Neonate 89 220-226.
119. J Contrino, PJ Krause, N Slover, et al. (1993) Elevated interleukin-1 expression in human neonatal neutrophils. Pediatr Res 34 249-252.
120. CA Hunter and SA Jones (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16 448-457.
121. C Gabay (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8(Suppl 2), S3.
122. E Bettelli, Y Carrier, W Gao, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 235-238.
123. G Kaplanski, V Marin, F Montero-Julian, et al. (2003) IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24 25-29.
124. N Nishimoto and T Kishimoto (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 619-626.
125. K Yamasaki, T Taga, Y Hirata, et al. (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241 825-828.
126. T Taga, M Hibi, Y Hirata, et al. (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58 573-581.
127. T Hirano, K Nakajima and M Hibi (1997) Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 8 241-252.
128. S Rose-John, J Scheller, G Elson, et al. (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80 227-236.
129. C Gerhartz, B Heesel, J Sasse, et al. (1996) Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphoty­rosine motif mediating STAT1 activation. J Biol Chem 271 12991-12998.
130. N Stahl, TJ Farruggella, TG Boulton, et al. (1995) Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267 1349-1353.
131. KW Liechty, JM Koenig, MD Mitchell, et al. (1991) Production of interleukin-6 by fetal and maternal cells in vivo during intraamniotic infection and in vitro after stimulation with interleukin-1. Pediatr Res 29 1-4.
132. A Yachie, N Takano, T Yokoi, et al. (1990) The capability of neonatal leukocytes to produce IL-6 on stimulation assessed by whole blood culture. Pediatr Res 27 227-233.
133. A Yachie, N Takano, K Ohta, et al. (1992) Defective production of interleukin-6 in very small premature infants in response to bacterial pathogens. Infect Immun 60 749-753.
134. J Dembinski, D Behrendt, R Martini, et al. (2003) Modulation of pro- and anti-inflammatory cytokine production in very preterm infants. Cytokine 21 200-206.
135. TA Markel, PR Crisostomo, GM Wairiuko, et al. (2006) Cytokines in necrotizing enterocolitis. Shock 25 329-337.
136. C Schultz, C Rott, P Temming, et al. (2002) Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res 51 317-322.
137. H Zola, M Fusco, PJ Macardle, et al. (1995) Expression of cytokine receptors by human cord blood lymphocytes: comparison with adult blood lymphocytes. Pediatr Res 38 397-403.
138. M Baggiolini and I Clark-Lewis (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307 97-101.
139. IF Charo and RM Ransohoff (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354 610-621.
140. JW Griffith, CL Sokol and AD Luster (2014) Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32 659-702.
141. GE White, AJ Iqbal and DR Greaves (2013) CC chemokine receptors and chronic inflammation—therapeutic opportunities and pharmacological challenges. Pharmacol Rev 65 47-89.
142. C Palmqvist, AJ Wardlaw and P Bradding (2007) Chemokines and their receptors as potential targets for the treatment of asthma. Br J Pharmacol 151 725-736.
143. CA Hebert, RV Vitangcol and JB Baker (1991) Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem 266 18989-18994.
144. I Kufareva, CL Salanga and TM Handel (2015) Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol Cell Biol 93 372-383.
145. C Murdoch and A Finn (2000) Chemokine receptors and their role in inflammation and infectious diseases. Blood 95 3032-3043.
146. WE Holmes, J Lee, WJ Kuang, et al. (1991) Structure and functional expression of a human interleukin-8 receptor. Science 253 1278-1280.
147. PM Murphy and HL Tiffany (1991) Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 253 1280-1283.
148. RM Richardson, RA DuBose, H Ali, et al. (1995) Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions. Biochemistry 34 14193-14201.
149. T Taniguchi, N Matsuzaki, K Shimoya, et al. (1993) Fetal mononuclear cells show a comparable capacity with maternal mononuclear cells to produce IL-8 in response to lipopolysaccharide in chorioamnionitis. J Reprod Immunol 23 1-12.
150. X Saez-Llorens and F Lagrutta (1993) The acute phase host reaction during bacterial infection and its clinical impact in children. Pediatr Infect Dis J 12 83-87.
151. JL Rowen, CW Smith and MS Edwards (1995) Group B streptococci elicit leukotriene B4 and interleukin-8 from human monocytes: neonates exhibit a diminished response. J Infect Dis 172 420-426.
152. KR Schibler, MS Trautman, KW Liechty, et al. (1993) Diminished transcription of interleukin-8 by monocytes from preterm neonates. J Leukoc Biol 53 399-403.
153. J Dembinski, D Behrendt, J Reinsberg, et al. (2002) Endotoxin-stimulated production of IL-6 and IL-8 is increased in short-term cultures of whole blood from healthy term neonates. Cytokine 18 116-119.
154. J Dembinski, D Behrendt, A Heep, et al. (2002) Cell-associated interleukin-8 in cord blood of term and preterm infants. Clin Diagn Lab Immunol 9 320-323.
155. LL Jones and DA Vignali (2011) Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res 51 5-14.
156. G Trinchieri (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 133-146.
157. S Goriely, MF Neurath and M Goldman (2008) How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol 8 81-86.
158. DA Vignali and VK Kuchroo (2012) IL-12 family cytokines: immunological playmakers. Nat Immunol 13 722-728.
159. M Kobayashi, L Fitz, M Ryan, et al. (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170 827-845.
160. B Oppmann, R Lesley, B Blom, et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 715-725.
161. S Pflanz, JC Timans, J Cheung, et al. (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 16 779-790.
162. DH Presky, H Yang, LJ Minetti, et al. (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 93 14002-14007.
163. CM Bacon, EF Petricoin 3rd, JR Ortaldo, et al. (1995) Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci U S A 92 7307-7311.
164. RX Wang, CR Yu, IM Dambuza, et al. (2014) Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20 633-641.
165. CL Langrish, JC Buddle, AJ Thrasher, et al. (2002) Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin Exp Immunol 128 118-123.
166. JW Upham, PT Lee, BJ Holt, et al. (2002) Development of interleukin-12-producing capacity throughout childhood. Infect Immun 70 6583-6588.
167. S Goriely, B Vincart, P Stordeur, et al. (2001) Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol 166 2141-2146.
168. CJ Chen, JW Hou and BL Chiang (2014) The difference in immune response and IL-12p35 methylation between newborns and adults. J Biomed Sci 21 76.
169. CV Ramana, MP Gil, RD Schreiber, et al. (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23 96-101.
170. K Schroder, PJ Hertzog, T Ravasi, et al. (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75 163-189.
171. JE Darnell Jr, IM Kerr and GR Stark (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 1415-1421.
172. H Okamura, H Tsutsi, T Komatsu, et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 88-91.
173. JF Bazan, JC Timans and RA Kastelein (1996) A newly defined interleukin-1? Nature 379 591.
174. T Ghayur, S Banerjee, M Hugunin, et al. (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386 619-623.
175. Y Gu, K Kuida, H Tsutsui, et al. (1997) Activation of interferon-gamma inducing factor mediated by interleukin-1β converting enzyme. Science 275 206-209.
176. CA Dinarello (2007) Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27 98-114.
177. CA Dinarello, D Novick, S Kim, et al. (2013) Interleukin-18 and IL-18 binding protein. Front Immunol 4 289.
178. JK Lee, SH Kim, EC Lewis, et al. (2004) Differences in signaling pathways by IL-1β and IL-18. Proc Natl Acad Sci U S A 101 8815-8820.
179. TR La Pine, JL Joyner, NH Augustine, et al. (2003) Defective production of IL-18 and IL-12 by cord blood mononuclear cells influences the T helper-1 interferon gamma response to group B Streptococci. Pediatr Res 54 276-281.
180. Y Li, X Li, X Zhou, et al. (2013) Impact of sepsis on the urinary level of interleukin-18 and cystatin C in critically ill neonates. Pediatr Nephrol 28 135-144.
181. FY Liew, NI Pitman and IB McInnes (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10 103-110.
182. E Lefrancais, S Roga, V Gautier, et al. (2012) IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 109 1673-1678.
183. S Ali, M Huber, C Kollewe, et al. (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 104 18660-18665.
184. J Schmitz, A Owyang, E Oldham, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 479-490.
185. K Oboki, T Ohno, N Kajiwara, et al. (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 107 18581-18586.
186. JC Alves-Filho, F Sonego, FO Souto, et al. (2010) Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 16 708-712.
187. C Cayrol and JP Girard (2009) The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 106 9021-9026.
188. J Ashley-Martin, L Dodds, TE Arbuckle, et al. (2015) Predictors of interleukin-33 and thymic stromal lymphopoietin levels in cord blood. Pediatr Allergy Immunol 26 161-167.
189. DF Fiorentino, MW Bond and TR Mosmann (1989) Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170 2081-2095.
190. W Ouyang, S Rutz, NK Crellin, et al. (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29 71-109.
191. KN Couper, DG Blount and EM Riley (2008) IL-10: the master regulator of immunity to infection. J Immunol 180 5771-5777.
192. M Saraiva and A O'Garra (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10 170-181.
193. S Pestka, CD Krause, D Sarkar, et al. (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22 929-979.
194. JL Mege, S Meghari, A Honstettre, et al. (2006) The two faces of interleukin 10 in human infectious diseases. Lancet Infect Dis 6 557-569.
195. AS Ho, Y Liu, TA Khan, et al. (1993) A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A 90 11267-11271.
196. W Slayton (2000) Development of the immune system in the human fetus. RD Christensen (Eds) Hematologic problems of the neonate Philadelphia: WB Saunders 21-41.
197. I Roth, DB Corry, RM Locksley, et al. (1996) Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med 184 539-548.
198. CA Jones, RG Cayabyab, KY Kwong, et al. (1996) Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res 39 966-975.
199. A Kotiranta-Ainamo, J Rautonen and N Rautonen (1997) Interleukin-10 production by cord blood mononuclear cells. Pediatr Res 41 110-113.
200. A Vigano, S Esposito, D Arienti, et al. (1999) Differential development of type 1 and type 2 cytokines and beta-chemokines in the ontogeny of healthy newborns. Biol Neonate 75 1-8.
201. C Schultz, P Temming, P Bucsky, et al. (2004) Immature anti-inflammatory response in neonates. Clin Exp Immunol 135 130-136.
202. J Hu-Li, EM Shevach, J Mizuguchi, et al. (1987) B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J Exp Med 165 157-172.
203. AN McKenzie, JA Culpepper, R de Waal Malefyt, et al. (1993) Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A 90 3735-3739.
204. F Brombacher (2000) The role of interleukin-13 in infectious diseases and allergy. Bioessays 22 646-656.
205. A Kelly-Welch, EM Hanson and AD Keegan (2005) Interleukin-13 (IL-13) pathway. Sci STKE 2005(293), cm9.
206. K Kawakami, J Taguchi, T Murata, et al. (2001) The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97 2673-2679.
207. AD Keegan, JA Johnston, PJ Tortolani, et al. (1995) Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation. Proc Natl Acad Sci U S A 92 7681-7685.
208. W Ouyang, SH Ranganath, K Weindel, et al. (1998) Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 9 745-755.
209. GR Lee, PE Fields and RA Flavell (2001) Regulation of IL-4 gene expression by distal regulatory elements and GATA-3 at the chromatin level. Immunity 14 447-459.
210. N Uzuner, A Babayigit Hocaoglu, D Olmez Erge, et al. (2013) Raised interleukin-13 levels in cord blood increases the risk of allergic sensitization at 5 years of age. Iran J Allergy Asthma Immunol 12 107-114.
211. K Hebel, S Weinert, B Kuropka, et al. (2014) CD4+ T cells from human neonates and infants are poised spontaneously to run a nonclassical IL-4 program. J Immunol 192 5160-5170.
212. G Herberth, J Heinrich, S Roder, et al. (2010) Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of life. Pediatr Allergy Immunol 21 5-13.
213. TJ Williams, CA Jones, EA Miles, et al. (2000) Fetal and neonatal IL-13 production during pregnancy and at birth and subsequent development of atopic symptoms. J Allergy Clin Immunol 105 951-959.
214. SR Paul, F Bennett, JA Calvetti, et al. (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci U S A 87 7512-7516.
215. T Zheng, Z Zhu, J Wang, et al. (2001) IL-11: insights in asthma from overexpression transgenic modeling. J Allergy Clin Immunol 108 489-496.
216. T Putoczki and M Ernst (2010) More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 88 1109-1117.
217. V Bhandari and JA Elias (2006) Cytokines in tolerance to hyperoxia-induced injury in the developing and adult lung. Free Radic Biol Med 41 4-18.
218. WL Trepicchio, L Wang, M Bozza, et al. (1997) IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 159 5661-5670.
219. C Garbers and J Scheller (2013) Interleukin-6 and interleukin-11: same but different. Biol Chem 394 1145-1161.
220. DJ Hilton, AA Hilton, A Raicevic, et al. (1994) Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J 13 4765-4775.
221. H Dahmen, U Horsten, A Kuster, et al. (1998) Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions. Biochem J 331(Pt 3), 695-702.
222. K Matsubara, K Baba, H Nigami, et al. (2001) Early elevation of serum thrombopoietin levels and subsequent thrombocytosis in healthy preterm infants. Br J Haematol 115 963-968.
223. C Dame, M Cremer, M Ballmaier, et al. (2001) Concentrations of thrombopoietin and interleukin-11 in the umbilical cord blood of patients with fetal alloimmune thrombocytopenia. Am J Perinatol 18 335-344.
224. D Aderka (1996) The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 7 231-240.
225. H Engelmann, D Novick and D Wallach (1990) Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265 1531-1536.
226. F Van Hauwermeiren, RE Vandenbroucke and C Libert (2011) Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 22 311-319.
227. FI Hawari, FN Rouhani, X Cui, et al. (2004) Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci U S A 101 1297-1302.
228. GH Waetzig, P Rosenstiel, A Arlt, et al. (2005) Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J 19 91-93.
229. KJ Van Zee, T Kohno, E Fischer, et al. (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 89 4845-4849.
230. T van der Poll, J Jansen, D van Leenen, et al. (1993) Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 168 955-960.
231. CA Dinarello (2004) Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4 378-385.
232. C Garlanda, F Riva, E Bonavita, et al. (2013) Negative regulatory receptors of the IL-1 family. Semin Immunol 25 408-415.
233. CA Dinarello (2013) Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 25 389-393.
234. SA Greenfeder, P Nunes, L Kwee, et al. (1995) Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 270 13757-13765.
235. EV Granowitz, AA Santos, DD Poutsiaka, et al. (1991) Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 338 1423-1424.
236. JE Sims (2002) IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 14 117-122.
237. JG Giri, J Wells, SK Dower, et al. (1994) Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol 153 5802-5809.
238. JH Pruitt, MB Welborn, PD Edwards, et al. (1996) Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 87 3282-3288.
239. S Orlando, M Sironi, G Bianchi, et al. (1997) Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem 272 31764-31769.
240. DE Smith, R Hanna, F Della, et al. (2003) The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18 87-96.
241. D Novick, D Elbirt, G Miller, et al. (2010) High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 34 121-126.
242. S Nourshargh and R Alon (2014) Leukocyte migration into inflamed tissues. Immunity 41 694-707.
243. M Kelly, JM Hwang and P Kubes (2007) Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 120 3-10.
244. K Ley, C Laudanna, MI Cybulsky, et al. (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7 678-689.
245. EW Raines and N Ferri (2005) Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 46 1081-1092.
246. J Reutershan and K Ley (2004) Bench-to-bedside review: acute respiratory distress syndrome—how neutrophils migrate into the lung. Crit Care 8 453-461.
247. WL Lee and GP Downey (2001) Neutrophil activation and acute lung injury. Curr Opin Crit Care 7 1-7.
248. D Vestweber (2007) Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol Rev 218 178-196.
249. CR Mackay (2001) Chemokines: immunology's high impact factors. Nat Immunol 2 95-101.
250. LE Kilpatrick, S Sun, D Mackie, et al. (2006) Regulation of TNF mediated antiapoptotic signaling in human neutrophils: role of delta-PKC and ERK1/2. J Leukoc Biol 80 1512-1521.
251. LE Kilpatrick, YH Song, MW Rossi, et al. (2000) Serine phosphorylation of p60 tumor necrosis factor receptor by PKC-δ in TNF-α-activated neutrophils. Am J Physiol Cell Physiol 279 C2011-C2018.
252. EM Bulger and RV Maier (2000) Lipid mediators in the pathophysiology of critical illness. Crit Care Med 28 N27-N36.
253. BP Leung, S Culshaw, JA Gracie, et al. (2001) A role for IL-18 in neutrophil activation. J Immunol 167 2879-2886.
254. WL Trepicchio, M Bozza, G Pedneault, et al. (1996) Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 157 3627-3634.
255. LE Kilpatrick, JY Lee, KM Haines, et al. (2002) A role for PKC-δ and PI 3-kinase in TNF-α-mediated antiapoptotic signaling in the human neutrophil. Am J Physiol Cell Physiol 283 C48-C57.
256. C Akgul and SW Edwards (2003) Regulation of neutrophil apoptosis via death receptors. Cell Mol Life Sci 60 2402-2408.
257. JC Marshall (2001) Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29 S99-S106.
258. RJ Shebuski and KS Kilgore (2002) Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 300 729-735.
259. T Gluck and SM Opal (2004) Advances in sepsis therapy. Drugs 64 837-859.
260. JE Portielje, WH Kruit, AJ Eerenberg, et al. (2001) Interleukin 12 induces activation of fibrinolysis and coagulation in humans. Br J Haematol 112 499-505.
261. TT Keller, AT Mairuhu, MD de Kruif, et al. (2003) Infections and endothelial cells. Cardiovasc Res 60 40-48.
262. RR Schleef, MP Bevilacqua, M Sawdey, et al. (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263 5797-5803.
263. D Pajkrt, T van der Poll, M Levi, et al. (1997) Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 89 2701-2705.
264. MG Netea, BJ Kullberg and JW Van der Meer (2000) Circulating cytokines as mediators of fever. Clin Infect Dis 31(Suppl 5), S178-S184.
265. CA Dinarello (2004) Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 10 201-222.
266. JB Tatro (2000) Endogenous antipyretics. Clin Infect Dis 31(Suppl 5), S190-S201.
267. H Moshage (1997) Cytokines and the hepatic acute phase response. J Pathol 181 257-266.
268. T Cartmell, GN Luheshi, SJ Hopkins, et al. (2001) Role of endogenous interleukin-1 receptor antagonist in regulating fever induced by localised inflammation in the rat. J Physiol 531 171-180.
269. C Gabay and I Kushner (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 448-454.
270. LE Jensen and AS Whitehead (1998) Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 334(Pt 3), 489-503.
271. P Loyer, G Ilyin, Z Abdel Razzak, et al. (1993) Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 336 215-220.
272. H Tilg, CA Dinarello and JW Mier (1997) IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 18 428-432.
273. MM Levy, MP Fink, JC Marshall, et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 1250-1256.
274. M Schouten, WJ Wiersinga, M Levi, et al. (2008) Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83 536-545.
275. WC Aird (2007) Endothelium as a therapeutic target in sepsis. Curr Drug Targets 8 501-507.
276. RS Hotchkiss, G Monneret and D Payen (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13 260-268.
277. SJ van Deventer (2000) Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 26(Suppl 1), S98-S102.
278. PV Giannoudis, M van Griensven, E Tsiridis, et al. (2007) The genetic predisposition to adverse outcome after trauma. J Bone Joint Surg Br 89 1273-1279.
279. GW Waterer and RG Wunderink (2003) Science review: genetic variability in the systemic inflammatory response. Crit Care 7 308-314.
280. DJ Minnich and LL Moldawer (2004) Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls. Proc Nutr Soc 63 437-441.
281. J Cohen, S Opal and T Calandra (2012) Sepsis studies need new direction. Lancet Infect Dis 12 503-505.
282. DC Angus (2011) The search for effective therapy for sepsis: back to the drawing board? JAMA 306 2614-2615.
283. RS Hotchkiss, G Monneret and D Payen (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13 862-874.
284. C Meisel, JC Schefold, R Pschowski, et al. (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180 640-648.
285. MW Hall, NL Knatz, C Vetterly, et al. (2011) Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 37 525-532.
286. F Venet, AP Foray, A Villars-Mechin, et al. (2012) IL-7 restores lymphocyte functions in septic patients. J Immunol 189 5073-5081.
287. WJ Wiersinga, SJ Leopold, DR Cranendonk, et al. (2014) Host innate immune responses to sepsis. Virulence 5 36-44.
288. B Lu, C Wang, M Wang, et al. (2014) Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol 10 713-727.
289. H Yang, H Wang, CJ Czura, et al. (2005) The cytokine activity of HMGB1. J Leukoc Biol 78 1-8.
290. H Wang, O Bloom, M Zhang, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 248-251.
291. H Wang, H Yang and KJ Tracey (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255 320-331.
292. T Calandra, B Echtenacher, DL Roy, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6 164-170.
293. CE McCall and BK Yoza (2007) Gene silencing in severe systemic inflammation. Am J Respir Crit Care Med 175 763-767.
294. E Abraham and M Singer (2007) Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35 2408-2416.
295. NC Riedemann, RF Guo and PA Ward (2003) Novel strategies for the treatment of sepsis. Nat Med 9 517-524.
296. DL Palazzi, JO Klein and CJ Baker (2006) Bacterial sepsis and meningitis. JS Remington, JO Klein, CB Wilson, CJ Baker (Eds) Infectious diseases of the fetus and newborn infant Philadelphia: WB Saunders 247-295.
297. MC Harris and RA Polin (2005) Diagnosis of neonatal sepsis. AR Spitzer (Eds) Intensive care of the fetus and neonate St Louis: CV Mosby 1115-1123.
298. MC Harris and J Casey (2005) Prevention and treatment of neonatal sepsis. AR Spitzer (Eds) Intensive care of the fetus and neonate St Louis: CV Mosby 1125-1136.
299. AGS Philip (1985) Defense mechanisms and deficiences. AGS Philip (Eds) Neonatal sepsis and meningitis Boston: GK Hall 29-42.
300. CB Wilson (1986) Immunologic basis for increased susceptibility of the neonate to infection. J Pediatr 108 1-12.
301. M Nesin and S Cunningham-Rundles (2000) Cytokines and neonates. Am J Perinatol 17 393-404.
302. BC Paria, J Reese, SK Das, et al. (2002) Deciphering the cross-talk of implantation: advances and challenges. Science 296 2185-2188.
303. CP Speer (2001) New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 79 205-209.
304. MB Edelson, CE Bagwell and HJ Rozycki (1999) Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics 103 766-771.
305. A Torbe, R Czajka, A Kordek, et al. (2007) Maternal serum proinflammatory cytokines in preterm labor with intact membranes: neonatal outcome and histological associations. Eur Cytokine Netw 18 102-107.
306. I Vogel, AR Goepfert, P Thorsen, et al. (2007) Early second-trimester inflammatory markers and short cervical length and the risk of recurrent preterm birth. J Reprod Immunol 75 133-140.
307. JL Wynn, NZ Cvijanovich, GL Allen, et al. (2011) The influence of developmental age on the early transcriptomic response of children with septic shock. Mol Med 17 1146-1156.
308. GP Giacoia (1993) New approaches for the treatment of neonatal sepsis. J Perinatol 13 223-227.
309. JE Pennington (1993) Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 17(Suppl 2), S515-S519.
310. JL Wynn, J Neu, LL Moldawer, et al. (2009) Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis. J Perinatol 29 79-88.
311. JL Wynn, PC Seed and CM Cotten (2010) Does IVIg administration yield improved immune function in very premature neonates? J Perinatol 30 635-642.